Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer

Peptide vaccine treatment has attracted attention in recent years as a new therapy option for chemotherapy-resistant, advanced, unresectable cancer. The safety of peptide vaccination with HLA-A(*)2402-restricted URLC10-A24-177 and VEGFR1-A12-9 1084 epitope peptides (fixed 2-mg dose) was investigated...

Descripción completa

Detalles Bibliográficos
Autores principales: HIGASHIHARA, YOSHIE, KATO, JUNKO, NAGAHARA, AKIHITO, IZUMI, KENTARO, KONISHI, MASAE, KODANI, TOMOHIRO, SERIZAWA, NOBUKO, OSADA, TARO, WATANABE, SUMIO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928476/
https://www.ncbi.nlm.nih.gov/pubmed/24398900
http://dx.doi.org/10.3892/ijo.2013.2242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928476/
https://www.ncbi.nlm.nih.gov/pubmed/24398900
http://dx.doi.org/10.3892/ijo.2013.2242

Ejemplares similares